VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY

Alejandro Falcon Gonzalez; Fredericus Eskens; Francois Ghiringhelli; Mustafa Ozguroglu; Christian Caglevic; Mahmut Gumus; Diego Tosi; Julian Grenier; Lucia Gonzalez Cortijo; Andrew G. Robinson; Juanita Lopez; Maria C. Bell; Mariusz Kwiatkowski; Mehmet Ali Nahit Sendur; Stephan Kruger; Qi Liu; Robert C. Castellino; Robin Guo; Carlos Rojas

doi:10.1016/j.ijgc.2025.102743

Retour

VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY

Article de revue

Avec comité de lecture

VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY

Alejandro Falcon Gonzalez, Fredericus Eskens, Francois Ghiringhelli, Mustafa Ozguroglu, Christian Caglevic, Mahmut Gumus, Diego Tosi, Julian Grenier, Lucia Gonzalez Cortijo, Andrew G. Robinson, …

International journal of gynecological cancer, Vol.35(11), p.102743

11/2025

DOI: https://doi.org/10.1016/j.ijgc.2025.102743

Indicateurs

1 Consultations de la notice

Détails

Titre: VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY
Créateurs - sans rôle: Alejandro Falcon Gonzalez - Virgen del Rocío University Hospital, Sevilla, Spain
Fredericus Eskens - Erasmus MC Cancer Institute, Rotterdam, Netherlands
Francois Ghiringhelli - Georges François Leclerc Center, Dijon, France
Mustafa Ozguroglu - Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
Christian Caglevic - Fundación Arturo López Pérez Cancer Center, Santiago, Chile
Mahmut Gumus - Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey
Diego Tosi - Regional Cancer Institute of Montpellier, Montpellier, France
Julian Grenier - Sainte-Catherine Cancer Institute, Avignon, France
Lucia Gonzalez Cortijo - Quirónsalud Madrid University Hospital, Madrid, Spain
Andrew G. Robinson - Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Ontario, ON, Canada
Juanita Lopez - The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom
Maria C. Bell - Sanford Health, Sanford Gynecologic Oncology Clinic, Sioux Falls, SD, United States of America
Mariusz Kwiatkowski - Nicolaus Copernicus Provincial Hospital, Koszalin, Poland
Mehmet Ali Nahit Sendur - Ankara Yıldrım Beyazıt University Faculty of Medicine and Ankara Bilkent City Hospital, Department of Medical Oncology, Ankara, Turkey
Stephan Kruger - Merck & Co., Inc., Rahway, NJ, United States of America
Qi Liu - Merck & Co., Inc., Rahway, NJ, United States of America
Robert C. Castellino - Merck & Co., Inc., Rahway, NJ, United States of America
Robin Guo - Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
Carlos Rojas - Department Medical Oncology, Bradford Hill Centro de Investigación Clínica, Santiago, Chile
Détails de publication: International journal of gynecological cancer, Vol.35(11), p.102743
Éditeur: Elsevier Inc
Identifiants: 99162819009311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article